Lupin launches Hydrocortisone Valerate Cream
22nd Nov 2019

Lupin has launched Hydrocortisone Valerate Cream USP, 0.2%, having received an approval from the United States Food and Drug Administration (USFDA) earlier.

The company’s Hydrocortisone Valerate Cream USP, 0.2%, is the generic equivalent of Westcort Cream, 0.2%, of Sun Pharmaceutical Industries Inc. It is indicated for the relief of the Inflammatory and pruritic manifestations of corticosteroid responsive dermatoses in adult patients.

Hydrocortisone Valerate Cream USP, 0.2%, (RLD: Westcort Cream) had an annual sales of approximately $11.5 million in the U.S. (IQVIA MAT September 2019).

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.